MedTrace Logo

Impact of Introduction of PHiD-CV for Nunavik Children, Quebec, Canada

NCT01694329 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 1420

Last updated 2017-03-03

No results posted yet for this study

Summary

The objective of this study is to document the residual burden of acute upper respiratory infections (AURIs), acute lower respiratory infections (ALRIs), otitis media (OMs) and auditory functional and anatomical abnormalities in children under the age of 5 years in Nunavik who will be exposed to PHiD-CV in combination with PCV-7 or PCV-13. The comparison groups will be the cohorts of children who received no PCV vaccine (those born in 1994-1996) and those exposed to PCV-7 exclusively (those born in 2003-2007).

Conditions

  • Acute Upper Respiratory Infection
  • Acute Lower Respiratory Tract Infection
  • Otitis Media (OM)
  • Invasive Pneumococcal Disease, Protection Against

Sponsors & Collaborators

  • GlaxoSmithKline

    collaborator INDUSTRY

  • CHU de Quebec-Universite Laval

    lead OTHER

Principal Investigators

  • Philippe De Wals, MD PhD · Centre de recherche du CHUQ

Eligibility

Max Age
5 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2012-09-30
Primary Completion
2017-12-31
Completion
2017-12-31

Countries

  • Canada

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01694329 on ClinicalTrials.gov